• QuartzBio, life science technology company providing portfolio-scale sample and biomarker intelligence for clinical-stage biopharma, secured strategic growth investment and controlling interest from Eir Partners on May 13, 2026.
• Bourne Partners Holdings LLC served as exclusive financial adviser on transaction.
• Deal positions QuartzBio to accelerate product development focused on interoperability, AI-driven automation, analytics, enterprise scalability, security, compliance.
• QuartzBio platform aims to reduce operational risk in clinical trials by unifying biospecimen tracking, consent status, chain of custody, metadata, biomarker results across vendors and systems.
• Financial terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bourne Partners Holdings LLC published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.